![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition strenghens Amgen pipeline for rare, autoimmune and severe inflammatory diseases by gaining Horizon’s first-in-class medicines like Tepezza (teprotumumab-trbw), Krystexxa (pegloticase) And Uplizna (inebilizumab-cdon).
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Product Name: Tepezza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $2,780.0 million Upfront Cash: $2,780.0 million
Deal Type: Acquisition October 06, 2023
Details:
ADX-914 (bempikibart) is a fully human anti-IL-7R alpha antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, which is investigated for the treatment of severe alopecia areata.
Lead Product(s): Bempikibart
Therapeutic Area: Dermatology Product Name: ADX-914
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Q32 Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
HZN7734 (daxdilimab), an anti-ILT7 human monoclonal antibody that depletes certain dendritic cells, interrupting inflammation cycle and causes tissue damage in autoimmune conditions. It is being investigated for systemic lupus erythematosus and alopecia areata.
Lead Product(s): Daxdilimab
Therapeutic Area: Immunology Product Name: HZN-7734
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
Tepezza (teprotumumab-trbw), an insulin-like growth factor-1 receptor inhibitor, is being developed for the treatment of active thyroid eye disease (TED) in Japan. TEPEZZA is approved by the U.S. FDA as the first and only medicine for TED.
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Product Name: Tepezza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Tepezza (teprotumumab-trbw), an insulin-like growth factor-1 receptor inhibitor, is being developed for the treatment of active thyroid eye disease (TED) in Japan. TEPEZZA is approved by the U.S. FDA as the first and only medicine for TED.
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Product Name: Tepezza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
HZN-7734 (daxdilimab) is a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7) that depletes certain dendritic cells, to treat people with active proliferative lupus nephritis (LN).
Lead Product(s): Daxdilimab
Therapeutic Area: Immunology Product Name: HZN-7734
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Tepezza (teprotumumab-trbw) binds to IGF-1R and blocks its activation and signaling. It is approved by FDA for the treatment of patients with thyroid eye disease.
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Product Name: Tepezza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Tepezza (teprotumumab-trbw) binds to IGF-1R and blocks its activation and signaling. It is approved by FDA for the treatment of patients with thyroid eye disease.
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Product Name: Tepezza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2023
Details:
Tepezza (teprotumumab-trbw) binds to insulin-like growth factor-1 receptor (IGF-1R) and blocks its activation and signaling. It is being investigated in patients with thyroid eye disease.
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Product Name: Tepezza
Highest Development Status: Phase IVProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
HZN-4920 (dazodalibep) is a CD40 ligand antagonist that blocks T cell interaction with CD40-expressing B cells, disrupting the overactivation of the CD40 ligand co-stimulatory pathway. Several autoimmune diseases are associated with the overactivation of this pathway.
Lead Product(s): Dazodalibep
Therapeutic Area: Immunology Product Name: HZN-4920
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023